SG11202112917PA - Modified viral particles and uses thereof - Google Patents

Modified viral particles and uses thereof

Info

Publication number
SG11202112917PA
SG11202112917PA SG11202112917PA SG11202112917PA SG11202112917PA SG 11202112917P A SG11202112917P A SG 11202112917PA SG 11202112917P A SG11202112917P A SG 11202112917PA SG 11202112917P A SG11202112917P A SG 11202112917PA SG 11202112917P A SG11202112917P A SG 11202112917PA
Authority
SG
Singapore
Prior art keywords
viral particles
modified viral
modified
particles
viral
Prior art date
Application number
SG11202112917PA
Other languages
English (en)
Inventor
Leah Sabin
Christos Kyratsous
Sven Moller-Tank
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11202112917PA publication Critical patent/SG11202112917PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202112917PA 2019-05-24 2020-05-22 Modified viral particles and uses thereof SG11202112917PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962852791P 2019-05-24 2019-05-24
PCT/US2020/034328 WO2020242984A1 (en) 2019-05-24 2020-05-22 Modified viral particles and uses thereof

Publications (1)

Publication Number Publication Date
SG11202112917PA true SG11202112917PA (en) 2021-12-30

Family

ID=71094822

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202112917PA SG11202112917PA (en) 2019-05-24 2020-05-22 Modified viral particles and uses thereof

Country Status (19)

Country Link
US (1) US20220241430A1 (enrdf_load_stackoverflow)
EP (1) EP3976631A1 (enrdf_load_stackoverflow)
JP (3) JP2022533438A (enrdf_load_stackoverflow)
KR (1) KR20220011664A (enrdf_load_stackoverflow)
CN (2) CN113874386A (enrdf_load_stackoverflow)
AR (2) AR118997A1 (enrdf_load_stackoverflow)
AU (1) AU2020283537A1 (enrdf_load_stackoverflow)
BR (1) BR112021023692A2 (enrdf_load_stackoverflow)
CA (1) CA3140386A1 (enrdf_load_stackoverflow)
CL (2) CL2021003096A1 (enrdf_load_stackoverflow)
CO (1) CO2021017692A2 (enrdf_load_stackoverflow)
IL (1) IL288233A (enrdf_load_stackoverflow)
MA (1) MA56035A (enrdf_load_stackoverflow)
MX (1) MX2021014338A (enrdf_load_stackoverflow)
PE (1) PE20212357A1 (enrdf_load_stackoverflow)
PH (1) PH12021552887A1 (enrdf_load_stackoverflow)
SG (1) SG11202112917PA (enrdf_load_stackoverflow)
TW (1) TW202110869A (enrdf_load_stackoverflow)
WO (1) WO2020242984A1 (enrdf_load_stackoverflow)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20212357A1 (es) * 2019-05-24 2021-12-17 Regeneron Pharma Particulas virales modificadas y usos de estas
US20240124892A1 (en) * 2021-03-02 2024-04-18 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Adeno-associated viruses and methods and materials for making and using adeno-associated viruses
EP4314021A1 (en) * 2021-04-30 2024-02-07 Duke University Compositions comprising adeno-associated virus chimera capsid proteins and methods of using the same
WO2022271829A1 (en) * 2021-06-23 2022-12-29 Dyno Therapeutics, Inc. Capsid variants and methods of using the same
WO2023220603A1 (en) 2022-05-09 2023-11-16 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
EP4536836A1 (en) 2022-06-07 2025-04-16 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2025042462A2 (en) * 2023-08-24 2025-02-27 Ohio State Innovation Foundation Assays and methods for quality control of genome packaging for gene therapy
US20250122482A1 (en) * 2023-09-07 2025-04-17 Regeneron Pharmaceuticals, Inc. Production and purification of covalently surface modified adeno-associated virus
WO2025111473A1 (en) * 2023-11-21 2025-05-30 Regeneron Pharmaceuticals, Inc. Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005266A1 (en) 1995-07-25 1997-02-13 Introgene B.V. Methods and means for targeted gene delivery
CA2265460A1 (en) 1996-09-11 1998-03-19 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Aav4 vector and uses thereof
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
ATE402254T1 (de) 1998-05-28 2008-08-15 Us Gov Health & Human Serv Aav5 vektoren und deren verwendung
EP1127150B1 (en) 1998-11-05 2007-05-16 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
NZ618298A (en) * 2001-11-13 2015-04-24 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
US20100203083A1 (en) 2007-05-31 2010-08-12 Medigene Ag Mutated structural protein of a parvovirus
CN102711449B (zh) 2009-12-10 2015-01-07 瑞泽恩制药公司 生产重链抗体的小鼠
GB201002362D0 (en) 2010-02-11 2010-03-31 Isis Innovation Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
CA2904396A1 (en) * 2013-03-15 2014-09-18 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding aav vectors
WO2015137802A1 (en) * 2014-03-10 2015-09-17 Uniqure Ip B.V. Further improved aav vectors produced in insect cells
CA2942697A1 (en) 2014-03-21 2015-09-24 Lynn Macdonald Non-human animals that make single domain binding proteins
WO2015191508A1 (en) * 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
HUE066398T2 (hu) 2017-06-27 2024-07-28 Regeneron Pharma Tropizmusmódosított rekombináns vírusvektorok és azok alkalmazása genetikai anyag humán sejtekbe történõ célzott bevezetésére
MD3645553T2 (ro) * 2017-06-27 2023-07-31 Regeneron Pharma Particule virale recombinate modificate cu tropism și utilizările acestora pentru introducerea țintită a materialului genetic în celulele umane
PE20212357A1 (es) * 2019-05-24 2021-12-17 Regeneron Pharma Particulas virales modificadas y usos de estas

Also Published As

Publication number Publication date
CA3140386A1 (en) 2020-12-03
JP2022533438A (ja) 2022-07-22
PE20212357A1 (es) 2021-12-17
US20220241430A1 (en) 2022-08-04
MX2021014338A (es) 2022-01-06
IL288233A (en) 2022-01-01
JP2025119015A (ja) 2025-08-13
KR20220011664A (ko) 2022-01-28
AR124119A2 (es) 2023-02-15
MA56035A (fr) 2022-04-06
WO2020242984A9 (en) 2021-01-14
CN114989267A (zh) 2022-09-02
CL2023000629A1 (es) 2023-10-20
JP2025032110A (ja) 2025-03-11
CO2021017692A2 (es) 2022-01-17
AU2020283537A1 (en) 2021-12-16
WO2020242984A1 (en) 2020-12-03
EP3976631A1 (en) 2022-04-06
AR118997A1 (es) 2021-11-17
TW202110869A (zh) 2021-03-16
PH12021552887A1 (en) 2022-09-05
CN113874386A (zh) 2021-12-31
BR112021023692A2 (pt) 2022-01-04
CL2021003096A1 (es) 2022-09-20

Similar Documents

Publication Publication Date Title
IL288233A (en) Modified viral particles and their use
IL290102A (en) Viral vectors of cell lysis and their uses
IL271993A (en) Viral vectors of cell lysis and their uses
EP3778882A4 (en) COMPOSITION OF RECOMBINANT ONCOLYTIC VIRUS AND ASSOCIATED USE
IL280854A (en) Recombinant myxoma viruses and their use
IL307791B1 (en) Recombinant virus, preparations containing it and its uses
EP3704723C0 (en) IMPROVED MAGNETIC PARTICLES AND THEIR USES
IL289585A (en) DLL3-targeted antibodies and uses thereof
IL283278A (en) Liver unique promoters and their uses
IL291027A (en) Anti-steap1 antibodies and uses thereof
IL270989A (en) Oncolytic virus and method
SG11202112112UA (en) Anti-galectin-9 antibodies and uses thereof
IL287003A (en) Anti-integrin antibodies and their uses
SG10201905229VA (en) Anti-Dengue Virus Antibodies and Applications Thereof
IL291546A (en) Antibodies against kir3dl3 and their uses
IL291550A (en) Anti-il-27 antibodies and their uses
IL287503B1 (en) Thio-semicarbazide compounds and their use
GB201914174D0 (en) Acoustic particle manipulation
SG11202109278YA (en) Novel mogrosides and uses of the same
ZA201908358B (en) Coated particles and their uses
IL291280A (en) Antibodies against cd371 and their uses
ZA202104244B (en) Recombinant viruses and the uses thereof
GB201803363D0 (en) New materials and uses thereof
IL290516A (en) Compositions and their uses
IL288807A (en) Anti-talen antibodies and their uses